Targeting CYP17A1 in Polyendocrine Metabolic Ovarian Syndrome: Selectivity, Natural Products and Clinical Translation

Developing steroidogenesis-directed treatments for polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome (PCOS), requires reducing pathological androgen excess while preserving adrenal and ovarian function. The Cytochrome P450 enzyme CYP17A1 offers a compelling pharmacological target, but its dual 17α-hydroxylase and 17,20-lyase activities complicate selective targeting. This critical narrative review integrates CYP17A1 enzymology with ovarian–adrenal steroidogenesis, peripheral androgen activation and the pharmacology of synthetic inhibitors and natural products. We examine how substrate availability, P450 oxidoreductase, cytochrome b5 and tissue context influence the CYP17A1 catalytic activity and apparent inhibitor selectivity. AKR1C3-dependent androgen activation, 11-oxygenated androgens and neuroendocrine regulation provide complementary perspectives on treatment response. Across candidate interventions, biochemical inhibition, altered enzyme expression and reduced circulating testosterone represent distinct findings; none alone establishes clinically useful target engagement or therapeutic benefit. Selected natural products, including dihydrotanshinone and curcuminoids, provide biochemical evidence of steroidogenic enzyme modulation, whereas clinical studies of botanical preparations remain insufficient to establish CYP17A1-mediated efficacy. Experience with synthetic inhibitors further demonstrates that preferential lyase inhibition cannot be assumed to preserve adrenal or reproductive function. We propose a translational evaluation framework combining direct activity measurements, steroidogenic selectivity panels, assay-interference controls, exposure assessment and endocrine and reproductive safety with patient-relevant outcomes. CYP17A1-directed treatment remains investigational in PMOS/PCOS. Its clinical promise depends on demonstrating a therapeutic window that improves androgen-related symptoms or reproductive outcomes without compromising essential steroid physiology.

Authors

Publication Details

Journal
Preprints.org
Published
2026-11-18
DOI
https://doi.org/10.20944/preprints202611.1840.v1
Primary Topic
Ovarian function and disorders
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Targeting CYP17A1 in Polyendocrine Metabolic Ovarian Syndrome: Selectivity, Natural Products and Clinical Translation

K. Li, Amit V. Pandey, Jibira Yakubu
Preprints.org
Ovarian function and disorders
preprint

Targeting CYP17A1 in Polyendocrine Metabolic Ovarian Syndrome: Selectivity, Natural Products and Clinical Translation

K. Li, Amit V. Pandey, Jibira Yakubu
preprint en

Abstract

Developing steroidogenesis-directed treatments for polyendocrine metabolic ovarian syndrome (PMOS), previously termed polycystic ovary syndrome (PCOS), requires reducing pathological androgen excess while preserving adrenal and ovarian function. The Cytochrome P450 enzyme CYP17A1 offers a compelling pharmacological target, but its dual 17α-hydroxylase and 17,20-lyase activities complicate selective targeting. This critical narrative review integrates CYP17A1 enzymology with ovarian–adrenal steroidogenesis, peripheral androgen activation and the pharmacology of synthetic inhibitors and natural products. We examine how substrate availability, P450 oxidoreductase, cytochrome b5 and tissue context influence the CYP17A1 catalytic activity and apparent inhibitor selectivity. AKR1C3-dependent androgen activation, 11-oxygenated androgens and neuroendocrine regulation provide complementary perspectives on treatment response. Across candidate interventions, biochemical inhibition, altered enzyme expression and reduced circulating testosterone represent distinct findings; none alone establishes clinically useful target engagement or therapeutic benefit. Selected natural products, including dihydrotanshinone and curcuminoids, provide biochemical evidence of steroidogenic enzyme modulation, whereas clinical studies of botanical preparations remain insufficient to establish CYP17A1-mediated efficacy. Experience with synthetic inhibitors further demonstrates that preferential lyase inhibition cannot be assumed to preserve adrenal or reproductive function. We propose a translational evaluation framework combining direct activity measurements, steroidogenic selectivity panels, assay-interference controls, exposure assessment and endocrine and reproductive safety with patient-relevant outcomes. CYP17A1-directed treatment remains investigational in PMOS/PCOS. Its clinical promise depends on demonstrating a therapeutic window that improves androgen-related symptoms or reproductive outcomes without compromising essential steroid physiology.

Preprints.org
Ovarian function and disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon